THE bilateral trade between India and America has the potential to double and reach $280 billion in the next five years, India's top diplomat in the US has said, amidst intense negotiations between the two countries to resolve their trade differences.
In March, US Trade Representative Robert Lighthizer announced that the US will terminate India's designation as beneficiary developing country under the Generalised System of Preferences (GSP) programme.
India imposed retaliatory tariffs on 28 US products including almonds and apples from June 5, after the Trump administration revoked its preferential trade privileges.
Trade tensions between India and the US have been rising with US president Donald Trump complaining that tariffs imposed by New Delhi on American products were "no longer acceptable".
India-US bilateral trade has doubled in the last 10 years and potentially can double again in the next five years, Indian ambassador to the US Harsh Vardhan Shringla said on Wednesday (18).
"We're looking at $280bn (bilateral trade) in the next five years," the top Indian diplomat said, exuding confidence that the two countries would be able to sort out their trade differences to give a big boost to their strategic and economic partnership.
Referring to the significant two-way investments, there is a mutuality of interest and benefit in this economic partnership, Shringla said at the 'India on the Hill: Charting a Future for Indo-US Relations' event here on Wednesday.
Identifying the US as the "foremost partner" when it comes to trade, investments and technology, the Indian envoy noted that the issues are bound to come up for a bilateral relationship that has developed so fast.
"That is what we are dealing with today," he said in an apparent reference to the talks between the two countries to resolve their trade difference.
Asserting that the trade differences are not necessarily issues that are significant enough to impact the larger relationship, Shringla described them as a minor speed bumps that come along the way.
Officials of the two countries are in close contact on this issue. According to media reports, the officials are trying to finalise a trade deal before prime minister Narendra Modi and US president Trump meet in Houston on Sunday (22) and again in New York next week.
"They are in touch in trying to see how we can address some of the issues that are there. Some will need a little more time, but there are others that can be resolved more quickly. We are looking at how we can prioritise those and move forward," Shringla said without further details.
"I have no doubt that we will see not only a speedy resolution of some of the issues that constituted trade differences between our sides, and also on the issue of investment policy, we have taken an approach that emphasises continued liberalisation by investment regime," he said.
Shringla said the recent steps that have been taken were a point in that direction.
India is also looking at other policy changes that could assist in a greater involvement of US companies in India and vice versa, he said.
"Last year, we, for the first time purchased $4.5bn oil and gas from the US," he said, adding that this could double in the coming years.
"We are also looking at significant investments in the energy sector in the US," Shringla said.
Prime minister Modi would be meeting the top 15 chief executive officers of the energy sector in Houston, which is the global energy hub, the Indian Ambassador said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.